The Effect of LPC100 and LP140 on Bone Mineral Density in Postmenopausal Women: A Multicenter, Randomized, Placebo-Controlled Study.

modulation of gut microbiota by probiotics has been proposed as a target for intervention to reduce bone mineral density (BMD) loss in the postmenopausal period. This study aims to evaluate the effect of (L.) LPC100 and (L.) LP140 on BMD in postmenopausal women in a multicenter, randomized, double-blind, placebo-controlled trial. the primary outcome was the change in T-score of the lumbar spine measured by dual-energy X-ray absorptiometry assessed after twelve-month probiotic supplementation. Secondary outcomes included changes in serological markers of inflammation and calcium-phosphate metabolism, body mass index, gastrointestinal symptoms, and satisfaction with the intervention. a decrease in T-score indicating the progressive bone demineralization reached a statistically significant difference in the placebo group (from mean values of 0.06 ± 1.04 to -0.28 ± 1.12, = 0.041) but not in the probiotic group (0.19 ± 0.99 and -0.08 ± 1.05, respectively, = 0.125) with a -value = 0.089 between the groups. No significant differences were found in secondary outcomes with the exception of vitamin D concentration and a significant reduction in some gastrointestinal symptoms in the probiotic group. A significant decrease in vitamin D level was observed only in the placebo group ( = 0.014). Probiotics were safe and well tolerated. this study suggests that the oral administration of LPC100 and LP140 may be a viable strategy to prevent BMD loss and vitamin D deficiency in postmenopausal women, but further research is necessary to confirm clinical benefits and to know the mechanism of action [ClinicalTrial.gov NCT06375668].